KalVista Partners with Pendopharm to Commercialise Sebetralstat for Hereditary Angioedema in Canada
Friday, June 27, 2025
KalVista Pharmaceuticals has entered into a licensing agreement with Pendopharm to support the commercialisation of its oral hereditary angioedema (HAE) treatment, sebetralstat, in Canada.
Sebetralstat is an investigational oral treatment designed for on-demand use in people with HAE. It works by inhibiting plasma kallikrein, which plays a role in the biochemical pathway that causes the swelling attacks typical of the condition. Regulatory applications have been submitted for patients aged 12 years and older, with further studies under way to assess its use in children aged 2 to 11.
HAE is a rare genetic condition caused by a deficiency or malfunction of the C1 esterase inhibitor protein, leading to excessive activation of the kallikrein-kinin system. This results in sudden, often painful swelling in various parts of the body. Most currently available on-demand treatments must be administered via injection, whereas sebetralstat, if approved, could become the first oral option, potentially improving convenience and quality of life for patients.
Under the agreement, Pendopharm will take responsibility for managing the regulatory approval process and commercial rollout of sebetralstat in the Canadian market.
The partnership forms part of KalVista’s strategy to expand global access to the therapy. Financial details of the agreement have not been disclosed.
Source: kalvista.com
